HRP20220201T1 - Postupak za pripremu pleuromutilina - Google Patents

Postupak za pripremu pleuromutilina Download PDF

Info

Publication number
HRP20220201T1
HRP20220201T1 HRP20220201TT HRP20220201T HRP20220201T1 HR P20220201 T1 HRP20220201 T1 HR P20220201T1 HR P20220201T T HRP20220201T T HR P20220201TT HR P20220201 T HRP20220201 T HR P20220201T HR P20220201 T1 HRP20220201 T1 HR P20220201T1
Authority
HR
Croatia
Prior art keywords
compound
formula
image
mixture
organic solvent
Prior art date
Application number
HRP20220201TT
Other languages
English (en)
Inventor
Rosemarie Riedl
Lee Spence
Werner Heilmayer
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Publication of HRP20220201T1 publication Critical patent/HRP20220201T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/41Y being a hydrogen or an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08Lactic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/76Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/80Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings
    • C07C2603/82Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings having three condensed rings with in total fourteen carbon atoms and having a having a [5.4.3.0(1,8)] ring structure, e.g. pleuromutiline
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Claims (5)

1. Postupak za pripravu spoja formule I [image] u obliku jednog stereoizomera u kristalnom obliku, naznačeno time, da postupak uključuje uklanjanje zaštite amino skupini bilo u spoju formule Ila [image] u smjesi spoja formule Ila sa spojem formule Ilb [image] gdje je R zaštitna skupina za amin, i izoliranje spoja formule I dobivene u obliku jednog dijastereomera u kristalnom obliku ili izravno iz reakcijske smjese ili rekristalizacijom u organskom otapalu, pri čemu se spoj formule I izolira u oblik jednog dijastereomera u kristalnom obliku te se sastoji od jednog od sljedećih koraka: a) tretiranja otopine spoja formule I u jednom stereoizomernom obliku dobivenom u polarnom organskom otapalu CH2Cl2, s protuotapalom odabranim između diizopropiletera (DIPE) ili terc-butil metil etera (MTBE), po mogućnosti DIPE b) tretiranja otopine spoja formule I u jednom stereoizomernom obliku dobivenom u polarnom organskom otapalu CH2Cl2, nakon koncentriranja s alkoholom, kao što je n-butanol; c) uzimanja izoliranog sirovog materijala spoja formule I u jednom stereoizomernom obliku, u eteru, npr. tetrahidrofuran (THF), i izborno tretiranje s protuotapalom odabranim između DIPE ili MTBE; d) dobivanja spoja formule I u obliku jednog dijastereomera u kristalnom obliku putem (re-)kristalizacije u organskom otapalu, pri čemu je organsko otapalo alkohol, kao što je n-butanol.
2. Postupak u skladu s patentnim zahtjevom 1, naznačeno time, da se nadalje sastoji iz sljedećeg koraka e) rekristalizacija kristalnog spoja dobivenog iz alkohola, kao što je n-butanol.
3. Postupak u skladu s patentnim zahtjevom 1 ili zahtjevom 2, naznačeno time, da se spoj formule IIa ili smjesa spoja formule IIa sa spojem formule IIb dobiva spajanjem bilo kojeg spoja formule IIIa [image] ili smjesa spoja formule IIIa sa spojem formule IIIb [image] odnosno pri čemu je R kao što je definirano u patentnom zahtjevu 1, s aktiviranim 14-O-AKT-acetil-mutilinom, pri čemu je AKT aktivirajuća skupina, po izboru mesil, besil, tosil ili -OAKT je halogen, po izboru 14-O-AKT-acetil-mutilin je spoj formule [image] i izoliranje ili spoja formule IIa ili smjese spoja formule IIa sa spojem formule IIb, odnosno dobiven iz reakcijske smjese.
4. Postupak u skladu s patentnim zahtjevom 3, naznačeno time, što spoj formule IIa ili smjesa spoja formule IIIa sa spojem formule IIIb se dobiva uklanjanjem zaštite tiolne funkcije bilo u spoju formule Iva [image] ili u smjesi spoja IVa sa spojem formule IVb [image] odnosno pri čemu je R kao što je definirano u patentnom zahtjevu 1, a R1 je tiol zaštitna skupina, i izoliranje ili spoja formule IIIa, ili smjese spoja formule IIIa sa spojem od formule IIIb, odnosno dobivene iz reakcijske smjese.
5. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time, što dalje uključuje korak pretvorbe spoja formule I u sol dodavanjem kiseline i izolacijom spoja u obliku soli, po izboru, kristalne soli.
HRP20220201TT 2010-05-26 2011-05-23 Postupak za pripremu pleuromutilina HRP20220201T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20100450092 EP2399904A1 (en) 2010-05-26 2010-05-26 Process for the preparation of pleuromutilins
EP17197350.6A EP3299356B1 (en) 2010-05-26 2011-05-23 Process for the preparation of pleuromutilins

Publications (1)

Publication Number Publication Date
HRP20220201T1 true HRP20220201T1 (hr) 2022-04-29

Family

ID=42937801

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220201TT HRP20220201T1 (hr) 2010-05-26 2011-05-23 Postupak za pripremu pleuromutilina

Country Status (29)

Country Link
US (1) US9120727B2 (hr)
EP (3) EP2399904A1 (hr)
JP (2) JP6038021B2 (hr)
KR (1) KR101935333B1 (hr)
CN (2) CN105111117A (hr)
AU (1) AU2011257938B2 (hr)
BR (1) BR112012029982A2 (hr)
CA (1) CA2799029C (hr)
DK (2) DK3299356T3 (hr)
EA (1) EA023273B1 (hr)
ES (2) ES2659729T3 (hr)
HK (1) HK1253006A1 (hr)
HR (1) HRP20220201T1 (hr)
HU (2) HUE035861T2 (hr)
IL (1) IL222999A (hr)
MA (1) MA34332B1 (hr)
MX (1) MX347176B (hr)
MY (1) MY164666A (hr)
NZ (1) NZ603804A (hr)
PL (2) PL3299356T3 (hr)
PT (2) PT3299356T (hr)
SG (1) SG185104A1 (hr)
SI (1) SI3299356T1 (hr)
TN (1) TN2012000506A1 (hr)
TR (1) TR201802636T4 (hr)
TW (1) TWI585073B (hr)
UA (1) UA108378C2 (hr)
WO (1) WO2011146954A1 (hr)
ZA (1) ZA201208056B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104447294A (zh) * 2014-11-24 2015-03-25 苏州乔纳森新材料科技有限公司 一种3-环己烯-1-甲酸的手性拆分方法
JP6818019B2 (ja) * 2015-06-17 2021-01-20 ナブリヴァ セラピュティクス ゲーエムベーハー レファムリンの注射可能医薬組成物
WO2016203011A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
PL3701944T3 (pl) 2015-06-18 2022-04-04 Estetra Srl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
CN107417586A (zh) * 2017-06-21 2017-12-01 华南农业大学 一种截短侧耳素类抗生素及其制备方法和应用
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI755055B (zh) 2019-09-18 2022-02-11 台灣神隆股份有限公司 用於製備惡拉戈利鈉及其中間體的方法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
EP4135682A1 (en) 2020-04-17 2023-02-22 Nabriva Therapeutics GMBH Therapeutic use of pleuromutilins
WO2021209173A1 (en) 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Novel therapeutic use of pleuromutilins
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207370A (ja) * 1985-03-11 1986-09-13 Seitetsu Kagaku Co Ltd 4−(メタンスルホニルオキシ)チオフエノ−ルの製法
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
MXPA05000984A (es) * 2002-07-24 2005-09-12 Sandoz Ag Derivados de pleuromutilina como antimicrobianos.
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
KR100745160B1 (ko) * 2003-08-04 2007-08-01 조인트 스탁 컴퍼니 그린덱스 멜도늄 염, 그것의 제조방법 및 그것을 주성분으로 한약학적 조성물
CA2536144C (en) * 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
ES2335284T3 (es) * 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
CA2659987A1 (en) 2006-07-20 2008-01-24 Wms Gaming Inc. Wagering game with special-event eligibility feature based on passive game play
EP1908750A1 (en) * 2006-10-05 2008-04-09 Nabriva Therapeutics Forschungs GmbH Process for the preparation of pleuromutilins
SI1961735T1 (sl) * 2007-02-22 2010-01-29 Indena Spa Postopek za pripravo acetatne soli (2r,3s)-3-fenilizoserin-metilestra
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2014645A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives and their use as antimicrobials
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds

Also Published As

Publication number Publication date
US9120727B2 (en) 2015-09-01
US20130079400A1 (en) 2013-03-28
TWI585073B (zh) 2017-06-01
ZA201208056B (en) 2014-01-29
MX2012013645A (es) 2013-05-01
BR112012029982A2 (pt) 2020-09-01
EP2576505B1 (en) 2017-11-29
CA2799029A1 (en) 2011-12-01
SG185104A1 (en) 2012-12-28
MA34332B1 (fr) 2013-06-01
PL2576505T3 (pl) 2018-05-30
DK2576505T3 (en) 2018-03-05
MX347176B (es) 2017-04-17
EA201291370A1 (ru) 2013-09-30
JP2013528162A (ja) 2013-07-08
EP2576505A1 (en) 2013-04-10
CN103080083B (zh) 2016-03-02
EP3299356B1 (en) 2021-11-24
EA023273B1 (ru) 2016-05-31
DK3299356T3 (da) 2022-01-31
KR101935333B1 (ko) 2019-01-04
PL3299356T3 (pl) 2022-04-04
AU2011257938B2 (en) 2016-06-23
JP2016210804A (ja) 2016-12-15
NZ603804A (en) 2014-03-28
CA2799029C (en) 2019-01-29
HK1253006A1 (zh) 2019-06-06
MY164666A (en) 2018-01-30
IL222999A0 (en) 2013-02-03
TW201209026A (en) 2012-03-01
CN105111117A (zh) 2015-12-02
HUE057587T2 (hu) 2022-05-28
PT2576505T (pt) 2018-03-05
WO2011146954A1 (en) 2011-12-01
IL222999A (en) 2016-02-29
CN103080083A (zh) 2013-05-01
EP2399904A1 (en) 2011-12-28
EP3299356A1 (en) 2018-03-28
KR20130079406A (ko) 2013-07-10
SI3299356T1 (sl) 2022-05-31
ES2659729T3 (es) 2018-03-19
JP6501742B2 (ja) 2019-04-17
TR201802636T4 (tr) 2018-03-21
UA108378C2 (uk) 2015-04-27
HUE035861T2 (hu) 2018-06-28
PT3299356T (pt) 2022-02-21
TN2012000506A1 (en) 2014-04-01
ES2909198T3 (es) 2022-05-05
JP6038021B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
HRP20220201T1 (hr) Postupak za pripremu pleuromutilina
NZ599306A (en) Process for the preparation of compounds useful as inhibitors of sglt2
EA201391522A1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
HRP20161501T1 (hr) Postupak za dobivanje supstituiranih (z)-alfa-fluor-beta-amino-akrilaldehida
HRP20161031T1 (hr) POSTUPCI ZA PRIPREMANJE (3R,3aS,6aR) HEKSAHIDRO-FURO[2,3-b]FURAN-3-OLA
BRPI0906906B8 (pt) Métodos para preparar um composto e compostos
RU2018126365A (ru) Способ расщепления амидных связей
UA102386C2 (ru) Способ получения алкил-2-алкоксимэтилен-4,4-дифтор-3-оксобутиратов
RU2014143116A (ru) Способы синтеза этилфумаратов и их применение в качестве промежуточных соединений
HRP20121026T1 (hr) Postupak za dobivanje kaspofungina i njegovih intermedijera
HRP20151422T1 (hr) Postupak za pripremu estera (5-fluoro-2-metil-3-hinolin-2-ilmetil-indol-1-il)-octene kiseline
RU2011139325A (ru) Аморфная соль макроциклического ингибитора hcv
EA201000147A1 (ru) Способ выделения и очистки монтелукаста
HRP20200488T1 (hr) Proizvodnja 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-ola
ATE475653T1 (de) Verfahren zur herstellung von valsartan
RU2013107023A (ru) Способ получения производных аминобензоилбензофурана
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
JP2016523246A5 (hr)
RU2013150600A (ru) Способ очистки микафунгина
WO2012103071A3 (en) Compounds and compositions
HRP20160414T1 (hr) Postupak sinteze derivata 3,6-dihidro-1,3,5-triazina
JP2017503016A5 (hr)
WO2012164242A8 (en) Process for the preparation of paliperidone
IN2013MU03596A (hr)
RU2013106503A (ru) Способ получения контрастных агентов